We conducted a study to quantitatively determine the pres sure perception thresholds in the oral cavity and oropharynx of a normal population with the PressureSpecifying Sensory Device (PSSD) . The PSSD measur ed pressure perception thresholds for both static and movin g one-and two-point discrimination moda lities at a variety ofsites in the oral cavity and oropharynx as well as in the forearm of11 adults. We also evaluated the ability ofthe PSSD to enhance sensory discrimination infour of these subjects by the pro cess of sensory re-education for 11 days over a 1S-day period. We f ound that the buccal mucosa and the tongue tip were the most sensitiv e sites in the oral cavity and oropharynx and that the flo or of the mouth and the soft palate were the least sensitiv e. Sensory discrimination in the oral cavity was enhanced in allfour subjects who underwent sensory re-education , although it returned to baseline levels over time after re-education was discontinued. The degree of intra-and intertester variability was minimal. Our data can be used as an aid in the developm ent of techniqu es to surgically restore sensation in the oral cavity and oropharynx.
surgery and radiotherapy to treat cancer in this area. In such patient s, an alteration of the anatomy, a loss of motor function , a lack of lubrication, and the presence of anesthesia or hypoesthesia ca n lead to funct iona l deficits.1,2 As a resu lt of advances in microvascular reconstructive surgery , restoration of the soft-tissue and bony anatomy in such patients can be achieve d in a very prec ise and predictable fashion.v' although restor ation of motor function and lubrication is not yet possible. Re-establishment of sensation has been addressed thro ugh the use of sensate (reinnervated) micro neurovascular free-tissue tran sfer , in which a micro neural repair is performed between a sensory nerve of the free flap and a recipient nerve in the head and neck ."?
To determine the success of surgery for sensory restoration, a qua ntitative assessment of senso ry recovery at the reconstructed area is crucial. The first step toward this goal is to obtain an accurate measurement of sensation in different parts of the oral cavity and orop harynx in a normal populat ion . In earlie r studies of sensory discrimination in the oral cavity , authors have exa mined the tip, dorsum; and ventral aspect of the tongue and the floor of the mouth.10-19 However, their techniques were not quantitative or completely comprehensive .
Sensory re-education is a method or combination of techniques that helps the patient with a sen sory impairment learn to reinterpret the altered profile of normal impu lses that reach the conscious level during neural regeneration. Sensory re-education improves the perception of sensory information that arises from receptors, and it increa ses the responsiveness of neurons in the som atosensory cortex .P:" In a study of the senso ry potenti al of free-flap donor sites, Brown et al showed that the process of sensory re-e duca tion at these sites resulted in enhancement of sensory perception.F Their findi ngs suggest that a 3-week course of sensory re-education can improve moving and static two-po int discrimination in selected surface areas of the human body.
We undertook a study to quantitati vely determine the pressure perception threshold s for both static and moving one-and two-point discrimination (s IPD, s2PD, mIPD, and m2PD) modalities in the oral cavity and oroph arynx of a normal popul ation with the Pressure-Speci fying Sensory Device ([PSSD] NK Biotechn ical Corp .; Minn eapolis). This instrum ent has previously been used by hand surgeons to measure sensory thresholds in the uppe r extremities, and it has proven to be a reliable and accurate tool for the objecti ve and quantitative measurement of sensation." We also sought to evaluate the ability of this device to enhance sensory discrimination in the oral cavity by sensory re-education .
Materials and methods
Equipment. Pressure percepti on thre sholds were quantified by the PSSD. Thi s device consists oftwo prongs with hemispheric end s (figur e I). Both prong s are mounted on force transducers that are housed within the device. The distance between the prongs (interpr ong distance) can be altered to obtain two-point discrimination readings at various sites. These transducers record the amount of force that is applied durin g determination of s IPD, s2PD, mIPD, and m2PD. The cross-sectional area of the hemispheric ends is 0.9 mm-. By dividing the force of application (in grams) by the cross-sectional area, one can calculate the pressure (g/mrn") at which the sensation is perceived. The PSSD is computer-linked, which allows for real-time data display, retrieval, and analysis.
Testing methods. To determin e s IPD, s2PD, mIPD, and m2PD values in the oral cavity and oropharynx, we tested II normal volunt eers-six men and five women , aged 27 to 51 years (mean: 34±5 )-who had no known neurolog ic impairment, history of radiation, or lesions in 684 the oral cavity or oropharynx. Sensory testing was performed in a quiet, distraction-free room. Each subject sat comfortably in a chair with the head immobilized on a headrest. The exam iner showe d the instrum ent to each subject and explained the testing concep t and then conducted one practice sess ion on the forear m. During each test, the examiner calibrated the instrum ent for gravity. The examiner then inform ed the volunteer that the actual test was to commence and slowly brought the prongs of the PSSD into cont act with the skin or muco sa. The pressure was slowly but steadily increased until the subject indicated perception of the stimulus by pressing a response button . The button was connected to the computer, which immediately displayed each value on the screen; information on the screen could not be seen by the subjects. The lowest threshold of s2PD was determined at various interprong distance s. Mucosal blanching or indentation was avoided durin g all testing. Each of the four discrimin ation determinations was made five times.
After the data were reviewed on the computer screen, the highest and lowest values were discarded , and the mean of the remain ing three values was recorded as the threshold for eac h determin ation. All tests were conducted at nine sites in the same sequence : forearm, lower lip, upper lip, buccal mucosa, floor of the mouth , tongue tip, lateral tongue, hard palate, and soft palate. All tests to establish normative data were performed by the same exa miner. Static and moving one-and two-point discrimination threshold s were determined on the right and left sides separately. All four modalities were tested at all nine sites.
Four of the II subje cts underwent sensory re-educ ation. Thi s was performed by touchin g the floor of the mouth with both prong s fixed at a distance of 13 mm. The s2PD thresholds were determined every day for 11 consecutive days, excluding weekend s. These four subjects returned for re-evaluation 2 weeks following the end of testing. The floor of the mouth was selected becau se normative data showed that this is the least sensitive site in the oral cavity . The interp rong distanc e was fixed at 13 mm because the threshold was maximum at this distance.
Statistical analysis. To evaluate intratester variability, the 11 subjec ts were studied by one of the testers for the pressure sensitivity threshold measurements. Tw o measurements (right and left sides) were performed at all nine sites. Correlation coefficients and 95% confidence intervals (CIs) were dete rmined between the right and left sides of the oral cavity and forearm. The results were reported as the mean (±SD) of the total number of sites measured by eac h mod ality.
Intertester variability was determined by measurin g the thresholds of s2PD by two experienced testers at two sites-the forearm and the floor of the mouth-in eight of the II subject s. Each of these eight subjects was evaluated by both testers, one after the other, without any period In addition, the followingadverse events R3% incidence ) werereportedatdosagesof 15-30mg/day inthecontrolled Clinical trial s:Headache(1 1%),Dyspepsia(7%),lacrimation (6%), Edema(5%) , Abdominal Pain (4%), Amblyopia (4%), Vomiting (4%), Pharyngitis (3%), Hypertension (3%). The followi ngevents were reportedwithtrea tedhead and neckcancer patients at inci dencesof 1%to2%at dosages of 7.5 to 30 mg/day: abnormal vision, conjunctivitis, dysphagia, epistaxs, myalgias, pruritus, rash, sinusitis, tachycar dia,tasteperversion, tremor, voiceaneranon.
The following events were reported rarely in treatedhead andneck cancerpalients « 1%): causal reli3liorr isunknown.
Body odor , hypothermia, mucous membrane abnormaltty , bradycardia, ECG abnormaltty, palpitati ons, syncope, anorexi a, increased appetite, esophagitis, gastro int estinal d i~rd e r , tongue di sorder , leukopenia, lymphadenopathy , anXiety, confusion, depression, abnormal dreams, hyperkinesia, hypesthesia, nervousness, paresthesias, speech disorder, twi tching, increased sputum, stri dor, yawning,seborrhea,deafness, eyepain, glaucoma,dysuria, metrorrhagia, urinaryimpairmerrl In long-term treatment were 2 patients with underlying cardiovascular diseaseofwhom 1experiencedamyocardial Infarctand another anepi sode of synco pe. The association withdrug Isuncert ai n.
Sjogren's SYndrome Patients: In controlled studies, 376 patients receive d pilocarpine, of whom 5%were menand 95%werewomen. Ra cedi stributionwas 64% caucasian 9% Onental, 3%Bl ack, and 4% of other ongi n. Mean a gw as55years.Themaj ority of patientswerebetween40and 69 years (70%), 16% were 70 years and older and 14% were younger then 40 years of age. Of these patients, 161/629 (89/376receivingpilocarpine)were overtheageof 65 years. The adverse events reported by those over 65 years and those 65 years andyounger were comparable exceptfornotabletrendsfor uri nary frequency, diarrhea, and dizz iness.The incidences of urinary frequencyand diarrhea In theelderlywere about double those in the non-elderly. The incidenceofdizzinesswas about 3timesashighinthe elderly as in the non-elderly. These adverse experiences were not considered to be serious. In the 2 placebocontrolled studi es,themost common adverse eventsrelated to drug use were sweating, uri nary frequency, chill s, and vasodilata tion (ftushing). Drug Interactions: Pilocarpine shouldbeadministeredwith cautio n to patients taki ng beta adrenergic antagonists becauseof the possi bility ofconductiondistu rbances. Drugs lvilli parasympathomi metic effects administeredconcurrently with pilo carpine would be expected to result in additive pharmacol ogic effects. Pil ocarpine might antagonize the anticholinergi c effects of drugs used concomitantiy. These effects sho uld be considered when anticholinergic properti es maybecontributi ngto thetherapeutic effect of concomitant medication(e.g.,atropine, inhaledipratropium). While no tormal drug interaction studies have been perf ormed, thefollowi ngconcomtt ant drugs were usedinat least 10% of patients in either or both Sjogren's efficacy studies: acetylsal icylic acid, artific ial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyr oxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol,andprednisone.
Carcinogenesis, Mutagenesis, Impainnent of Ferti lity: Ufetimeoral car cinogeni citystudieswereconducted in COl mi ceandSprague-Dawley rat s.Pilocarpinedid notinduce tumorsin mice at anydosage studied(upto30mg/kg/day, whichyiel ded a systemi c exposure approximately 50times larger than the maximum systemic exposure observed clinically). Inrats, a dosage of 18 mg/kg/day, whi chyielded a systemicexposure approxrnately 100times larger than the maximum systemic exposure observed clinica lly, resul tedinastatisticallysignllicant increase intheInci dence of benignpheochromocytomas in both males and females, and a statistically significant increase in the incidence of hepat ocellul aradenomas in female rats. The tumorigenictty observedinratswas observedonl yat alargemullipleofthe maxmum labeled clinical dose, and maynot be relevant to clinical use. No evidencethat pilocarpine has the potential to cause geneti c toxi ctty was obtai ned in a series of studies that included: 1) bacteri al assays (Salmonella and £ coli) for reverse gene mutations; 2) an in vitm chromosome aberration assay in a Ch inesehamster ova/)' cellline; 3)an in vivo chromosome aberration assay (micronucleus test ) in mice;and 4) a prima/)' DNA damageassay (unscheduled DNA synthesis) in rat hepatocyte primarycultures. Oraladministrationofpilocarpinetomale andfemaleratsat adosageof18mg/kg/day,whi chyi eldedasystemicexposure approxi mat ely1DO times larger than themaxmumsystemi c exposure observed clinically, resulted in impaired reproducti vefunction,incl uding reduced fertility, decreased sperm moW ity, and morphologic evidence of abnormal sperm.IIisunclearwhether thereducti oninferti litywasdue to eff ectson mal e animals, female animals, or both mal es and females. In dogs, exposureto pilocarpine at a dosage of 3 mg/k g/day (approximately 3 times the max imum recommended humandose whencomparedonthebasisof bodysurfacearea (mg/m')estimates) for6 months resulled inevidence ofimpairedspermatogenesis.Thedataobtained in these studies suggest that pilocarpine may impai r the fert ility of male and female humans. SAlAGEN' Tabl ets shoul d beadministered toindividualswho areattempti ngto conceiveachi ldonlyif thepotential benefrtjustifiespot ential impairment of fertil ity.
Pregnancy: Teratogenic Eff ects Pregnancy CategoryC: Pilocarpinewas associatedwtth a reduct on inthe meanfetal body weightand an increasein theincidenceof skeletal varlat ions when give n to pregnant ratsat a dosage of 90 mg/kg/day (approxi matel y 26 times themaximumrecommendeddosefor a50 kg human when compared on the basis of body surface area (mg/m') estimates). These effects may have been secondary to maternal toxicity. In another study, oral administra t on of pi locarpinetofemal eratsduring gestationandlactat onata dosage of 36 mg/kg/day (approxi mately 10 times the maxmum recommended dose for a 50 kg human VIflen compared on the basis of body surface area (mglm') estimates ) resultedin anincr eased incidence of still births ; decreasedneonatalsurvival andreducedmean body weight of pups were observed at dosages of 18 mg/kg/day (approximately 5 trnes themaxmum recommendeddose for a 50 kg human whencomparedon thebasi s of body surface area (mg/m') estimates) and above. There areno adequate andwell-eontrolledstudiesin pregnant women. SAlAGEN' Tablets should beused during pregnancy onlyII thepotentialbenefrt justifiesthe potential risktothefetus.
Nursing Mothers: It is not known whether this drug is exc reted in humanmilk.Because many drugsare excreted in human milk and because of the pot en fial for serious Adverse Event adverse reactionsinnursing infantsfromSAlAGEN' Tablets a deci sionshould be made whether to di scontinue nursing 0' to di scontinue the drug, taking into account the importanceof thedrugto the mother. CDNTRAJNDlCATIDNS:SAlAGEN' Tabietsare contraindicated inpatients withuncontrolledasthma,known hypersensitivity topilocarpine,andwhenmiOSisisundesirable,e.g., inacute iritisand in narrow-angle(angl e closure)glaucoma.
WARNINGS:
Putmonary Di sease: Pilocarpine has been report ed to increase airway resistance, bronch ial smooth musde tone andbronchial secretions. Pi locarpine hydrochloride should be admi nistered withcauti onto and under dose medical supervisi on in patients with controlled asthma, chronic bronchitis, or chronic obstruct ive pulmonary disease requiring pharmacotherapy.
PRECAUT IONS: General: Pil ocarpine toxicity is characterized by an exaggeration of its parasympathomimetic effects. These may indude: headache, visual disturbance lacrimation sweating, respiratory distress, gastrointesiinal spasm: nausea, vom iting, diarrhea, atrioventricular bl ock tachycardia, bradycardia,hypotension,hypertension,shocm ental conf usion,cardiac arrhythmia,and tremors. The dose-re late d cardiovascular pharmacologic effects of pilocarpine include hypotension, hypertension, bradycardia,and tachycar dia. Pilocarpine should beadmini stered with caution to patients wtth known or suspect ed cholelithiasis or bilia/)' tract disease. Contractions of the gallbladder or bili arysmooth muscle could precipitate complications incl udi ng cholecystitis, cholangitis,and bilia/)' obstruction. Pil ocarpine may increase ureteral smooth musde tone and could theoretically precipitate renal colic (or "ureteral reflUX"), particularly in patient s with nephrolithiasis. Ch olinergic agoni stsmay havedose-relatedcentral nervous sys tem effects. This should be considered when treating patientswith undenyi ngcogniti veorpsychiatri c disturbances.
Hepatic Insufficiency: Based on decreased plasma clearance observed in pati ents with moderate hepatic impairment, the starting dose in thesepatient s should be 5 mg twice daily, followed by adjustment based on therapeutic response and tolerabiltty. Patients with mild hepatic insufficiency (Chil d-Pugh score of 5-6) do not requiredosage reductions.To date, pharmacoki netic studies in subjects with severe hepatic impai rment (Child-Pugh score of 10- 1 5) of rest. The means (±SD), correlation coefficients, and 95% CIs were repor ted for both sites. A compact variable was created between the right and left sides for all analyses of oral cavity sites and the forear m, split by modality. The mos t and least sensitive areas of the ora l cav ity were determ ined by a paired t test betwee n each var iable and every other variable. Because this resulted in 28 comparisons, a Bonferoni correlatio n was applied to establish the more appropriate probability level (0.05/28 = 0.00 17).
PRESSURE-SPEC IFYING SENSORY DEVICE : Q UANTITATIVE SE NSO RY MEAS UREMENT IN THE ORA L CAVI TY AN D ORO PHAR YNX O F NO RMAL ADULTS
Therefore, statis tica l sig nificance was defined as p$. 0.00 17. A re pea te d measure s analys is of variance (AN OYA) was perform ed to determine individual subject varia bility over time .
Results
We found a highly sig nifica nt corre lation between the right and left sides of the oral cavity and the forearm for all modalities. The correlation coeffic ients and 95% CIs revealed good reprodu cibil ity between the right and left sides, suggesting strong intratester reliability (table I) . Likewi se, the mean (±SD) results, correlation coefficient s, and 95% CIs demon strated very reproducible result s and good intertester varia bility for forearm and floor of the mouth recordin gs perform ed during the s2PD modalit y (table 2) . The results of the point discrimination thresholds were reported by ora l cav ity sites, forearm, and modality (table 3) . The buccal mucosa and the tongue tip were found to be the most sensitive areas of the oral cavi ty, and the floor of the mouth and the soft palate were found to be the least sensitive ( figure 2) . Initially, all four subjects who participated in the sen- sory re-education comp onent of the investigation exp erienced significant impr ovement in their sensitivity at the floor of the mouth under the s2PD modality, but 2 weeks follow ing discontin uation of the stimulus, pressure thresholds in all four return ed to baseline levels (figure 3).
Discussion
The vario us modalities that have been used to assess sensation in other parts of the body (the hand in particular) are pain, touch, temperature, stereog nosis, proprioception, and vibration. Pain is assessed by applying a needle to the skin, and it is quantitatively meas ured by an algesimeter. " Proprioception is eva luated by physically moving the anatomic structure and assessing the subject's ability to detect the direction of move ment. Touch threshold can be quantified by the Semm es-Weinstein mon ofilament pressure esthesiometer," although an engineering analysis" of this device revealed that it has seve ral limitations. For example, variations in bucklin g stress gene rated within the monofilaments are difficult to avoid because chan ges in temp erature and hu midity can cause variations in the elastic modu les of the monofilament. Also, eve n slight changes in the meth od of application can gross ly skew the results of this discontinu ous mea surement. Finally, this instrument is extre mely awkward to use in the oral cav ity and orop hary nx. Stereognosis is the term used for the tactile recognition of objects, and it can be quantitatively assesse d by twopoint discrimin ation testing." Of all the tests that measure sensatio n, two-poi nt discrimination is believed to be the best at measuring functional sensation.P:" Fun ctional (1) the higher the level of the initial injury is, the greater is the retrograde damage to the cell body , (2) regenerating axons must successfully cross the site of nerve repair, (3) regenerating axons must locate an endoneural sheath that once housed a sensory axon , and (4) regenerating axon s must success fully reinnervate a sensory end organ .
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sensation is the term used to connote the ability of the anatomic area being tested to perform a basic task. The s2PD determination is an evaluation of the inner vation density of the slowly adapting fiber receptor system, and the m2PD determination is an evaluation of the rapidly adapting fiber receptor system. The result s of our study suggest that the PSSD can accurately measure pressure perception in the oral cavity and oropharynx for both of these fiber-receptor systems . An important feat ure of the PSSD is that it provides data points for eac h test from a continuous scale, and these point s are recorded and stored by a computer program. In our study, the degree of intra-and intertester variabi lity was minimal. To overcome the anatomic and technical constraints of measuring sensation in the oral cavity and oropharynx , the instrum ent was modified by the senior author (U.K.S.), who extended the length of the prongs so that quantit ative measurement of sensation in hardto-reach areas such as the soft palate and lateral pharyngeal wall could be obtained. Even so, the PSSD has three limitations in particular: it is expensi ve, it requires two examiners and a cooperative patient, and testing all sites takes approximately 30 minutes .
Recovery of functional sensation is often not satisfactory after nerve transection and repair because of 
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In the event of ove rdose, consider standard measures to remove any unabsorbed drug. Symptomatic and supportive treatm ent is recommended . Desloratadine and 3-hydroxydesloratadineare not elimi nated byhemodialysis.
Lethalit y occurred in rats at oral doses of 250 mg/kg or greater (estimated desloratadine and desloratadine metabolite exposures we re approximately 120 times the AUCin humans at the recommended dail y oral dose). The oral med ian lethal dose in mice was 353 mg/kg (estimated desloratadine expos ures were approximately 290 times the human daily oral dose on a mg/m 2 basis). No deaths occu rred at oral doses up to 250 mg/kg in monkeys (estimated desloratadin e exposures were app roximately 810 times the human daily oral dose ona mg/m 2 basis). o -L... ., ---,---,-------r---,---,-------,----,---.,.------,---,-- tion for diseased patients at the outset of trainin g is lower than that of normals.
Scher ingCorporation
In our study, the PSSD provided an acc urate and objecti ve analysis of sensory discrimination in the oral cavity and oropharynx. A great deal of further investigation needs to be undertaken to ascertain the range of sensory perception in normal subjects. Studies should also be condu cted in patients with neurolo gic, infectiou s, and neopl astic disease s that affect the entire sensory pathway, from the sensory receptor to the central nervous system.The impact of therapeutic intervention in this region must also be determined so that we might better understand the effect of ablative and recon structive surgery as well as radiation and chemotherapy. It is only throu gh quantit ative analysis of the sensory thresholds that we can hope to determine the impac t of anesthes ia and hypoesthesia on the function of this region. Our prelim inary work represents a critic al step tow ard designing new surgical and rehabilitative strategies for restoring a higher level of function than what is currently possible . animals follow ing the transection of a peripheral nerve. P? These cortical changes may be partly responsible for the dimini shed sensory recovery following nerve repair and rege neration in human s because (1) regener ated nerves may reac tivate only a frac tion of their normal cortical space , (2) enlarged cortical represent ation of adjace nt skin terr itories suggests a possible compen satory hypersensitivity of these areas, and (3) discontinuous and patchy cortical represent ation can lead to false localization.
Despite the periph eral and cortical disorganization, experimental and clinic al evidence strongly sugges ts that the level of functional sensation can be improved after nerve repair.31 Based on the results of their clinical studies, Parry and Salter" and Dellon " concluded that sensory re-education-as measured by long-term improvements in localization, tactile gnosis, and two-point discrimination-is possible in the adult following nerve repair. Sensory re-education can imp rove the sensory funct ion of uninjured fingertips; such a benefit is seen when a blind person learns braille. Orner reported that the norm al value for two-point discrimination was 3 to 5 mm in a sighted control gro up and 1.5 to 2 mm among a group of blind braille readers." The value of sensory re-e ducation was further reinforce d by Brown et a1,2 2 The results of their study sugges t that a 3-wee k course of sensory re-edu cation with the Disk-Crim inator can improve s2PD and m2PD in selected regio ns of the human body. Our study showe d that impro vement of sensation in the oral cavity among normal subjects through sensory training is certainly possible. However, the durability of that enh anced sensory discrimination is questionable in light of the return to baseline that occurred once the trainin g regimen was halted. Howe ver, the loss of impro vement in the norm al state cannot necessarily be extrapolated to the diseased or rehabilitated state, becau se the level of sensa-
